NO981746L - Utlevering av biologisk aktive polypeptider - Google Patents

Utlevering av biologisk aktive polypeptider

Info

Publication number
NO981746L
NO981746L NO981746A NO981746A NO981746L NO 981746 L NO981746 L NO 981746L NO 981746 A NO981746 A NO 981746A NO 981746 A NO981746 A NO 981746A NO 981746 L NO981746 L NO 981746L
Authority
NO
Norway
Prior art keywords
biologically active
delivery
active polypeptides
polypeptides
antigens
Prior art date
Application number
NO981746A
Other languages
English (en)
Other versions
NO328224B1 (no
NO981746D0 (no
Inventor
Lothar Steidler
Erik Remaut
Jeremy Mark Wells
Richard William Falla Le Page
Original Assignee
Univ Cambridge Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cambridge Tech filed Critical Univ Cambridge Tech
Publication of NO981746D0 publication Critical patent/NO981746D0/no
Publication of NO981746L publication Critical patent/NO981746L/no
Publication of NO328224B1 publication Critical patent/NO328224B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
NO19981746A 1995-10-20 1998-04-17 Ikke-invasive, grampositive bakterier og anvendelse av disse til fremstilling av adjuvanser eller vaksiner. NO328224B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9521568.7A GB9521568D0 (en) 1995-10-20 1995-10-20 Delivery of biologically active polypeptides
PCT/GB1996/002580 WO1997014806A2 (en) 1995-10-20 1996-10-21 Delivery of biologically active polypeptides

Publications (3)

Publication Number Publication Date
NO981746D0 NO981746D0 (no) 1998-04-17
NO981746L true NO981746L (no) 1998-06-22
NO328224B1 NO328224B1 (no) 2010-01-11

Family

ID=10782670

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19981746A NO328224B1 (no) 1995-10-20 1998-04-17 Ikke-invasive, grampositive bakterier og anvendelse av disse til fremstilling av adjuvanser eller vaksiner.

Country Status (17)

Country Link
US (2) US6605286B2 (no)
EP (1) EP0871748B1 (no)
JP (2) JP2000508162A (no)
KR (1) KR19990064308A (no)
CN (1) CN1195860C (no)
AT (1) ATE435294T1 (no)
AU (1) AU7315496A (no)
BR (1) BR9610929A (no)
CA (1) CA2234941C (no)
DE (1) DE69637961D1 (no)
DK (1) DK0871748T3 (no)
ES (1) ES2328751T3 (no)
GB (1) GB9521568D0 (no)
NO (1) NO328224B1 (no)
NZ (1) NZ320418A (no)
WO (1) WO1997014806A2 (no)
ZA (1) ZA968806B (no)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
CA2297786C (en) * 1997-08-05 2011-06-14 Vlaams Interuniversitair Instituut Voor Biotechnologie New immunoprotective influenza antigen and its use in vaccination
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
AU749695B2 (en) * 1997-09-10 2002-07-04 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
DE69914932T2 (de) 1998-10-20 2004-12-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
FR2791998B1 (fr) * 1999-04-07 2001-06-08 Agronomique Inst Nat Rech Lactocoques modifies exprimant une catalase et leurs utilisations
DK1739178T3 (da) 1999-07-05 2010-11-22 Actogenix Nv Levering af trekløverpeptider
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
DE60236374D1 (de) 2001-03-23 2010-06-24 Advanced Bionutrition Corp Verfahren zur Herstellung eines Futtermittels enthaltend Bakterien für Aquakultur und seiner Verwendung
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
EP1513545B1 (en) 2002-06-19 2008-03-19 Actogenix N.V. Methods and means to promote gut absorption
EP1514183A2 (en) * 2002-06-20 2005-03-16 BRITISH TELECOMMUNICATIONS public limited company Distributed computer
US20050129711A1 (en) * 2002-11-14 2005-06-16 Janakiraman Ramachandran Incapacitated whole-cell immunogenic bacterial compositions produced by recombinant expression
CA2506031A1 (en) * 2002-11-15 2004-06-03 Vib Vzw Self-containing lactobacillus strain comprising a thya mutation and therapeutic applications thereof
GB0230331D0 (en) * 2002-12-31 2003-02-05 British Telecomm Method and apparatus for operating a computer network
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
JP4839209B2 (ja) * 2003-02-06 2011-12-21 アンザ セラピューティクス，インコーポレイテッド 改変された自由生活微生物、ワクチン組成物、およびそれらの使用方法
ATE552843T1 (de) * 2003-02-06 2012-04-15 Aduro Biotech Listerien deren eindringen in nicht-phagozytische zellen abgeschwächt ist, impfstoffe, die diese listerien enthalten und deren verwendungen
US7745157B2 (en) * 2003-02-21 2010-06-29 University Of Maryland, Baltimore Human lymphocyte medium adjuvant
US20070298012A1 (en) * 2003-12-16 2007-12-27 Ivan King Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules
GB0412655D0 (en) * 2004-06-07 2004-07-07 British Telecomm Distributed storage network
ES2439698T3 (es) 2004-08-20 2014-01-24 Actogenix N.V. Procedimiento para mejorar la conservación de lactococos
EP1786445B1 (en) 2004-08-25 2011-06-08 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Live microbial microbicides
WO2006021893A2 (en) 2004-08-26 2006-03-02 The University Of Western Ontario Pharmaceutical compositions comprising inhibitors of iron transport, and method of identifying iron transport inhibitors, fn staphylococcus aureus
MX2007012755A (es) 2005-04-15 2008-01-14 Univ North Carolina State Metodos y composiciones para modular la adhesion y tolerancia al estres en bacterias.
US9017662B2 (en) 2005-08-30 2015-04-28 Actogenix N.V. Anti-TNF alpha producing lactic acid bacteria for the treatment of chronic enterocolitis
EP1934349A4 (en) * 2005-08-30 2009-05-27 Commw Scient Ind Res Org BACTERIAL ADMINISTRATION OF BIOLOGICALLY ACTIVE POLYPEPTIDES
EP1957100B1 (en) 2005-11-29 2016-07-13 Intrexon Actobiotics NV Induction of mucosal tolerance to antigens
US8852916B2 (en) 2010-01-22 2014-10-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with microorganisms
US8278094B2 (en) 2005-12-14 2012-10-02 The Invention Science Fund I, Llc Bone semi-permeable device
US8734823B2 (en) * 2005-12-14 2014-05-27 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US20110172826A1 (en) * 2005-12-14 2011-07-14 Amodei Dario G Device including altered microorganisms, and methods and systems of use
BRPI0711119A2 (pt) * 2006-05-02 2011-08-30 Actogenix Nv administração microbiana de peptìdeos intestinais associados à obesidade
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US20100303777A1 (en) * 2006-12-14 2010-12-02 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
AU2008204442B2 (en) 2007-01-12 2013-03-14 Intrexon Actobiotics Nv Lactococcus promoters and uses thereof
EP2125010B1 (en) 2007-01-25 2014-06-04 Actogenix N.V. Treatment of immune disease by mucosal delivery of antigens using genetically modified lactobacillus
JP2012504116A (ja) * 2008-09-29 2012-02-16 アクトジェニックス・エヌブイ 粘膜での微生物のコロニー形成の低減
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
DK2424972T3 (da) 2009-04-30 2013-10-14 Actogenix Nv Kryobeskyttende midler til frysetørring af mælkesyrebakterier
EP2275527A1 (en) 2009-07-17 2011-01-19 ActoGeniX NV Animal component-free culture medium for bacterial fermentation
EP3192873A1 (en) 2009-09-29 2017-07-19 Intrexon Actobiotics NV Lactobacillus and streptococcus promoters and uses thereof
EP2343319A1 (en) 2010-01-07 2011-07-13 University of Ljubljana Genetically modified food grade microorganism for treatment of inflammatory bowel disease
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
AU2011268146A1 (en) 2010-06-17 2013-01-10 Actogenix Nv Compositions and methods for treating inflammatory conditions
CN101921725B (zh) * 2010-07-27 2013-06-05 浙江大学 一种口服免疫阻断鸡生长抑素作用的转化子及其应用
JP5991650B2 (ja) * 2010-08-10 2016-09-14 国立研究開発法人農業・食品産業技術総合研究機構 サイトカインを発現する豚丹毒菌及び豚丹毒菌を用いたサイトカインのデリバリー方法
JP6175428B2 (ja) 2011-06-01 2017-08-02 イントレクソン・アクトバイオテイクス・エヌブイＩｎｔｒｅｘｏｎ Ａｃｔｏｂｉｏｔｉｃｓ ＮＶ 細菌のポリシストロン性発現系
ES2676707T3 (es) 2011-09-23 2018-07-24 Intrexon Actobiotics Nv Bacterias gram positivas modificadas y usos de las mismas
HUE038336T2 (hu) 2011-09-23 2018-10-29 Intrexon Actobiotics Nv Módosított gram-pozitív baktériumok és alkalmazásaik
AU2013299605A1 (en) 2012-08-07 2015-03-26 TopGeniX, Inc. Topical composition comprising transformed bacteria expressing a compound of interest
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
KR102143856B1 (ko) * 2013-06-11 2020-08-12 하우스 웰니스 푸드 코퍼레이션 대식세포에 물질을 송달하는 담체
US10064797B2 (en) 2014-06-17 2018-09-04 TopGeniX, Inc. Topical formulations for UV protection
EP3020816A1 (en) * 2014-11-11 2016-05-18 University College Cork Bacterial mediated gene therapy
CN104476458B (zh) * 2014-11-14 2016-08-17 中黔电气集团股份有限公司 一种带自动夹紧机构的低压柜骨架组装台
EP3237622B1 (en) * 2014-12-23 2021-02-24 Ilya Pharma AB Methods for wound healing
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
DK3402499T3 (da) 2016-01-14 2021-09-27 Intrexon Actobiotics Nv Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
KR102553825B1 (ko) * 2018-05-04 2023-07-13 (주)메디톡스 표적 단백질을 코딩하는 폴리뉴클레오티드를 포함하는 재조합 미생물로부터 유래한 세포외 소낭 및 그의 용도
KR102015116B1 (ko) * 2018-05-04 2019-10-21 (주)메디톡스 표적 단백질을 코딩하는 폴리뉴클레오티드를 포함하는 재조합 미생물로부터 유래한 세포외 소낭 및 그의 용도
HRP20240085T1 (hr) * 2019-03-04 2024-03-29 Aurealis Therapeutics AG Prokariotski ekspresijski sustav indukciran kloridom

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874702A (en) * 1980-09-08 1989-10-17 Biogen, Inc. Vectors and methods for making such vectors and for expressive cloned genes
US5417986A (en) * 1984-03-16 1995-05-23 The United States Of America As Represented By The Secretary Of The Army Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
US5032510A (en) * 1984-09-26 1991-07-16 Eli Lilly And Company Method for expression and secretion in bacillus
IL76422A0 (en) * 1984-09-26 1986-01-31 Lilly Co Eli Method for expression and secretion in bacillus
US5504005A (en) * 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
US5591632A (en) * 1987-03-02 1997-01-07 Beth Israel Hospital Recombinant BCG
US5330753A (en) * 1987-04-29 1994-07-19 President And Fellows Of Harvard College Cholera vaccines
US6130082A (en) * 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
US5149532A (en) * 1989-11-01 1992-09-22 Cedars Sinai Medical Center Method of vaccine or toxoid preparation and immunization by colonization with recombinant microorganisms
GB9006400D0 (en) * 1990-03-22 1990-05-23 Ciba Geigy Ag Bacterial vectors
IL99097A0 (en) * 1990-09-05 1992-07-15 Akzo Nv Haemophilus paragallinarum vaccine
JP3415145B2 (ja) * 1991-03-05 2003-06-09 ザ ウエルカム ファウンデーション リミテッド 弱毒化細菌における組換えタンパク質の発現
IL103530A0 (en) * 1991-10-25 1993-03-15 Duphar Int Res Treponema hyodysenteriae vaccine
WO1993017117A1 (en) * 1992-02-27 1993-09-02 Lynxvale Limited Heterologous gene expression in lactococcus, and the expression products therefrom
US5455034A (en) * 1992-06-26 1995-10-03 Kansas State University Research Foundation Fusobacterium necrophorum leukotoxoid vaccine
US5837509A (en) * 1992-12-30 1998-11-17 Bioteknologisk Institut Recombinant lactic acid bacterium containing an inserted promoter and method of constructing same
IT1270123B (it) * 1994-10-05 1997-04-28 Dompe Spa Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
US5733540A (en) * 1995-03-08 1998-03-31 Lee; Peter Poon-Hang Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria
US5824538A (en) * 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
GB9518323D0 (en) * 1995-09-07 1995-11-08 Steidler Lothar Materials and methods relating to the attachment and display of substances on cell surfaces
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
US6261561B1 (en) * 1996-04-19 2001-07-17 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of stimulating an immune response by administration of host organisms that express intimin alone or as a fusion protein with one or more other antigens
US6685943B1 (en) * 1997-01-21 2004-02-03 The Texas A&M University System Fibronectin binding protein compositions and methods of use
PT892054E (pt) * 1997-06-20 2007-02-28 Intervet Int Bv Vacina de clostridium perfringens
US6100388A (en) * 1998-03-16 2000-08-08 Biogaia Biologies Ab Lactobacilli harboring aggregation gene as a vaccine delivery vehicle
US6190669B1 (en) * 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
DE69914932T2 (de) * 1998-10-20 2004-12-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
AU2002210401B2 (en) * 2000-10-20 2006-07-20 Bioneer A/S Fermentation method for production of heterologous gene products in lactic acid bacteria
US7425449B2 (en) * 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same

Also Published As

Publication number Publication date
CA2234941C (en) 2010-09-21
CN1202934A (zh) 1998-12-23
NO328224B1 (no) 2010-01-11
EP0871748A2 (en) 1998-10-21
WO1997014806A2 (en) 1997-04-24
JP2000508162A (ja) 2000-07-04
MX9803093A (es) 1998-11-29
BR9610929A (pt) 1999-12-21
ZA968806B (en) 1998-04-20
AU7315496A (en) 1997-05-07
US20030202991A1 (en) 2003-10-30
DE69637961D1 (de) 2009-08-13
DK0871748T3 (da) 2009-10-19
ES2328751T3 (es) 2009-11-17
JP2008067708A (ja) 2008-03-27
GB9521568D0 (en) 1995-12-20
US20010006642A1 (en) 2001-07-05
ATE435294T1 (de) 2009-07-15
CN1195860C (zh) 2005-04-06
WO1997014806A3 (en) 1997-08-21
CA2234941A1 (en) 1997-04-24
NO981746D0 (no) 1998-04-17
EP0871748B1 (en) 2009-07-01
KR19990064308A (ko) 1999-07-26
NZ320418A (en) 2000-03-27
US6605286B2 (en) 2003-08-12

Similar Documents

Publication Publication Date Title
NO981746L (no) Utlevering av biologisk aktive polypeptider
FI962154A0 (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
NO953278D0 (no) Fremgangsmåter for in vivo-levering av biologisk aktive stoffer og sammensetninger som er nyttige for dette
FI964681A (fi) Ihmisperäiset Lactobacillus-kannat, niitä sisältävät valmisteet ja niiden käytöt
MY118371A (en) Tetrahydrolipstatin containing compositions
ATE267613T1 (de) Arzneimittel und deren verwendung
GEP20053420B (en) Sustained Release Ranolanolazine Formulation
AP9801392A0 (en) Concentrated antibody preparation.
DK0839026T3 (da) Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler
HUP0101293A2 (hu) AspB28-humán inzulint tartalmazó inhalációs gyógyászati készítmény és alkalmazása
NZ337246A (en) Pharmaceutical composition comprising amoxycillin and clavulanate
HUP9800635A2 (hu) In vivo exogén transzfekcióra és expresszióra használható gyógyászati kombináció
ES8707488A1 (es) Un metodo para preparar maleato de 2-terc-butilamino-3'-cloropropiofenona
BR9707083A (pt) Formas sólidas de administração com liberação instantánea e processos para a sua produção
PT1144420E (pt) Fosfatidilinositois sulfatados a sua preparacao e a sua utilizacao
AU2229997A (en) Pharmaceutical compositions comprising natural human alpha-interferon
IT1252160B (it) Composizioni farmaceutiche contenenti il peptidoglicano del lactobacillus casei
GB9921985D0 (en) Medicaments containing pantothenic acid
DK0927031T3 (da) Farmaceutisk sammensætning indeholdende nimesulid til oral admnistration
MX9706412A (es) Uso de aerogeles inorganicos en la industria farmaceutica.
UA30911A (uk) Спосіб поліхіміотерапії хворих деструктивним туберкульозом легень
MX9604539A (es) Aminoacidos modificados para la distribucion de farmaco.
GEP20002177B (en) Ointment “Levaskani” for Treatment of Wounds and Burns

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees